Jiangsu Institute of Hematology

Sequential CAR T-Cell Therapy and Autologous Stem Cell Transplant Shows 97% Survival Rate in Ph-Negative B-ALL

- A phase 2 trial of sequential CD22/CD19 CAR T-cell therapy combined with autologous stem cell transplant achieved a 97% two-year overall survival rate in 37 patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. - The "sandwich" strategy demonstrated progressive deepening of remissions, with 100% of patients achieving complete remission after the first CAR T-cell infusion and 93% maintaining molecular remission after the second infusion. - The treatment showed a favorable safety profile with no severe cytokine release syndrome or neurotoxicity, positioning it as a potential alternative to allogeneic stem cell transplant. - All 35 patients who completed the full treatment regimen survived, with 80% maintaining continuous measurable residual disease-negative status at median 28-month follow-up.